secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2021-12-15T23:59:59+00:00
Accession:  0000950170-21-005217
Event type: leadership
Sentiment:  positive
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector appoints Sara Kenkare-Mitra as President and Head of R&D
----------------------------------------------------------------

- Dr. Kenkare-Mitra joins from Genentech, most recently SVP of Development Sciences.
- Annual base salary of $570,000; eligible for 100% bonus and $500,000 sign-on bonus.
- Equity grants: 300,000 stock options (4-yr vest), 59,000 RSUs (3-yr vest), 59,000 PSUs (1-yr performance-based vest).
- She will report to CEO Arnon Rosenthal and lead all immuno-neurology and oncology R&D efforts.
- Effective December 15, 2021; includes standard change-in-control and severance agreement (Tier 2).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017021005217/0000950170-21-005217-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017021005217/alec-20211215.htm
  HTML page:      https://secwatch.observer/filing/0000950170-21-005217

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer